Market research
RB0.F REGENXBIO Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 452M
- P/E ratio
- Not available
- Analyst target
- 65.13
- Dividend yield
- Not available
- Beta
- 0.94
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US75901B1070
- Market cap
- 452M
- P/E ratio
- Not available
- Analyst target
- 65.13
- Dividend yield
- Not available
- Beta
- 0.94
About
About REGENXBIO Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RB0.F discussion.
5 years, 5 months ago
REGENXBIO Inc is currently in a long term uptrend where the price is trading 0.9% above its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.2.
REGENXBIO Inc's total revenue rose by 82.2% to $21M since the same quarter in the previous year.
Its net income has dropped by 74.7% to $-46M since the same quarter in the previous year.
Finally, its free cash flow grew by 200.2% to $27M since the same quarter in the previous year.
Based on the above factors, REGENXBIO Inc gets an overall score of 4/5.